BeOne Medicines AG (NASDAQ: ONC) is highlighted as one of the High Growth International Stocks to Buy Now, with Buy ratings from Bernstein and Barclays. The first-in-world approval of Sonrotoclax in China for two blood cancers drove the bullish sentiment, with impressive response rates in studies presented at the 2025 ASH conference.

The MCL study showed a 52.4% overall response rate, while the CLL/SLL study demonstrated a 77% ORR, leading to global rollout plans. Rebecca Liang from Bernstein sees ONC as undervalued, emphasizing the potential of Sonrotoclax as “best-in-class.” The Swiss-based company focuses on innovative cancer treatments for hematology and solid tumors.

While ONC shows promise, other AI stocks may offer greater upside potential with less downside risk. Investors interested in an undervalued AI stock can explore opportunities in the market. The article originally published on Insider Monkey offers insights into potential investment options for those seeking growth in the AI sector.

Read more at Yahoo Finance: Bernstein Remains a Buy on BeOne Medicines AG (ONC)